Polestar Automotive Holding UK PLC (PSNY) Secures $200M Investment to Accelerate EV Expansion
Polestar Automotive Holding UK PLC (NASDAQ:PSNY) tops our list for being one of the cheap stocks to buy. It is a Swedish EV company founded in 2017 and focuses on producing premium battery electric vehicles with a strong emphasis on innovation and sustainability. Its product lineup includes the Polestar 2 sedan, Polestar 3 and 4 SUVs, Polestar 5 grand-touring sedan, and the Polestar 6 roadster.
Switch Auto Insurance and Save Today!
Great Rates and Award-Winning Service
The Insurance Savings You Expect
Affordable Auto Insurance, Customized for You
As of mid-2025, Polestar Automotive Holding UK PLC (NASDAQ:PSNY) is demonstrating strong operational momentum and expanding strategically. In Q2 2025, the company reported retail sales of 18,049 vehicles, marking a 38% year-over-year increase. Sales in the first half of 2025 rose by 51% compared to the same period in 2024, driven by increasing consumer demand and market penetration. In Q1 2025 alone, sales surged 76% year-over-year, with gross margins turning positive at 7%, aided by a favorable sales mix and cost control.
To support future growth, the business is expanding its manufacturing capabilities through a strategic partnership with Volvo Cars. The upcoming Polestar 7, a premium compact SUV slated for launch in 2028, will be manufactured in Kosice, Slovakia. This decision enhances the corporation's production capacity, leverages Volvo's established infrastructure, and strengthens its position in the competitive electric SUV market.
A fleet of electric light vehicles recharging their batteries in a parking lot.
Additionally, the company secured a $200 million equity investment from PSD Investment Limited, linked to Geely's founder, bolstering its financial position to scale operations and roll out new models. While Polestar Automotive Holding UK PLC (NASDAQ:PSNY)'s trajectory shows promise, it must continue addressing typical EV start-up challenges, including cost structure management and cash flow improvements.
While we acknowledge the potential of PSNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53%
Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions A total of 17 investors have a majority stake in the company with 50% ownership Insiders have been selling lately We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Nektar Therapeutics (NASDAQ:NKTR) should be aware of the most powerful shareholder groups. With 53% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's delve deeper into each type of owner of Nektar Therapeutics, beginning with the chart below. Check out our latest analysis for Nektar Therapeutics What Does The Institutional Ownership Tell Us About Nektar Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Nektar Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nektar Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 13% of Nektar Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Charles Schwab Investment Management, Inc. is the largest shareholder with 8.3% of shares outstanding. BVF Partners L.P. is the second largest shareholder owning 7.4% of common stock, and Millennium Management LLC holds about 5.4% of the company stock. A closer look at our ownership figures suggests that the top 17 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Nektar Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Nektar Therapeutics in their own names. It has a market capitalization of just US$397m, and the board has only US$4.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. General Public Ownership With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Nektar Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Nektar Therapeutics has 4 warning signs (and 3 which can't be ignored) we think you should know about. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
26 minutes ago
- Yahoo
Results: Exponent, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Last week, you might have seen that Exponent, Inc. (NASDAQ:EXPO) released its quarterly result to the market. The early response was not positive, with shares down 5.4% to US$68.33 in the past week. Exponent reported US$133m in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$0.52 beat expectations, being 5.6% higher than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. After the latest results, the three analysts covering Exponent are now predicting revenues of US$530.2m in 2025. If met, this would reflect a modest 2.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to decrease 2.3% to US$1.98 in the same period. Before this earnings report, the analysts had been forecasting revenues of US$529.8m and earnings per share (EPS) of US$1.97 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. View our latest analysis for Exponent There were no changes to revenue or earnings estimates or the price target of US$88.00, suggesting that the company has met expectations in its recent result. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Exponent analyst has a price target of US$100.00 per share, while the most pessimistic values it at US$76.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Exponent's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 6.8% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.8% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Exponent. The Bottom Line The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$88.00, with the latest estimates not enough to have an impact on their price targets. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Exponent analysts - going out to 2027, and you can see them free on our platform here. Even so, be aware that Exponent is showing 1 warning sign in our investment analysis , you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
Investor With $941K Portfolio Considers Liquidating It All To Pay-Off Mortgage: 'When Does The Grind End?'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. 'When does the grind end?' That's the question a cryptocurrency investor with a $941,000 portfolio asked his followers last week, wondering whether it was time to quit the turbulent world of cryptocurrency investing and retire to a more peaceful life. 'The urge to liquidate everything, pay off my home, and finally live debt-free is hitting hard today,' the cryptocurrency trader under the username 'Sergio' said. 'I keep wrestling with the same question: Do I keep chasing more... or is a simpler life, free of debt and pressure, actually the real wealth?' Don't Miss: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. Sergio decried the emotional, mental and physical cost of his current lifestyle while suggesting that there did not appear to be an end in sight. 'Some days it feels like no matter how much I make, it's never enough,' he said. 'But what is enough? When does the grind end? When do I stop feeling like I have to keep climbing?' Sergio said he was still young and had the energy to keep going, but part of him now dreamt of walking away from it all. That part of him wondered whether 'peace might be the biggest win of all.' Unsurprisingly, Sergio's post struck a chord with many cryptocurrency investors. Commenting on the post, 'Cryptofada' encouraged Sergio to take the bold step. Trending: $100k+ in investable assets? – no cost, no obligation. 'The biggest regret will not be buying a house and you see a potential to make [sic] extra 100-300k, the BIGGEST REGRET will be realizing that some part of the money gone and yet you still do [sic] monthly contribution to your house,' they said. 'Pay [sic] house and be free of monthly mortgage and see how your life will turn around.' More cautiously, Base Product Lead Nick Prince suggested that Sergio start by liquidating only a percentage of his portfolio to avoid regrets. Meanwhile, Alpine Fox LP Managing Partner Mike Alfred said the freedom Sergio sought did not have to be mutually exclusive from his continued financial success. 'It's not binary,' Alfred said. 'I make millions every year and also have no mortgage. The foundation is solid and I still strive for more at the same time.' 'I did [sic] because I could and I thought my family would be better protected long term that way irrespective of what happens to me physically or financially,' he post encapsulates the challenges of trying to achieve financial independence while being trapped by growing debts, bills and obligations, and how the effort can easily turn into an endless pursuit. The desire to escape the rat race and answer the question of what is enough is what has led to the proliferation of movements like Financial Independence, Retire Early. Adherents of the philosophy try to achieve financial independence earlier than the conventional retirement age through aggressive savings, budgeting and investments so that they can eventually live on passive income. But at the end of the day, the power lies with the individual to decide what is enough. Read Next: With Point, you can Image: Shutterstock This article Investor With $941K Portfolio Considers Liquidating It All To Pay-Off Mortgage: 'When Does The Grind End?' originally appeared on Sign in to access your portfolio
